Overview
Why was this study conducted?
The study tested a new combined vaccine against malaria and hepatitis B. The new combined
vaccine was developed for use in babies at risk of both malaria and hepatitis B.
Researchers wanted to find out if the new combined vaccine had the same ability to protect against
hepatitis B infection as the licensed vaccine.
What was studied? Who was in this study?
508 babies from Burkina Faso and 197 from
Body defenses (called “antibodies”)
Ghana. These 705 babies got their first
against hepatitis B.
vaccination between 8 and 12 weeks of age.
Side effects
Main results
About the same proportion of babies had protective Hepatitis B antibody levels after receiving the
new combined vaccine or the licensed hepatitis B vaccine. The side effects did not raise any specific
safety concern.
NCT number: NCT01345240
EudraCT number: 2011-001508-37